Journal of Humanities, Arts and Social Science

ISSN Print: 2576-0556 Downloads: 197047 Total View: 1817179
Frequency: monthly ISSN Online: 2576-0548 CODEN: JHASAY

Should Psychedelic Drugs Be Offered as a Treatment for Mental Illness?

Ruoqi Zhang

The Institute for International Research on Criminal Policy (IRCP), Ghent University, Gent, Belgium.

*Corresponding author: Ruoqi Zhang

Published: March 13,2023


Psychedelics are becoming increasingly popular as an entry point into difficult- to-treat psychiatric illnesses and a supplement to existing treatments. However, many people view these substances with caution due to increased incidents where they've been used illegally in unsupervised settings. This paper argues that adding psychedelics to the treatment of mental illness can be beneficial for both patients and society as a whole. These drugs could help those who suffer from conditions such as anxiety or depression by providing them with new perspectives on their problems. Additionally, psychedelic therapy may provide psychiatrists with additional options when treating more severe cases of disorders such as PTSD or bipolar disorder. This paper will discuss the clinical effects and physiological processes of action of psychedelic substances, which justifies their use in psychotherapy from three perspectives. First, it will cover the history of these drugs, explaining how they have been used throughout different cultures for centuries. Second, it will examine the safety and efficacy of using psychedelics in therapy. Third, this article provides arguments for why psychedelic therapies should be utilized by therapists across a variety of disciplines.


Argento, E., Strathdee, S. A., Tupper, K., Braschel, M., Wood, E., & Shannon, K. (2017). Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open, 7(9), e016025.

Belouin, S. J., & Henningfield, J. E. (2018). Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology, 142, 7-19.

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of Psychopharmacology (Oxford, England), 29(3), 289-299.

Canal, C. E., & Murnane, K. S. (2016). The serotonin 5-HT2Creceptor and the non-addictive nature of classic hallucinogens. Journal of Psychopharmacology, 31(1), 127-143.

Carhart-Harris, R. L., Erritzoe, D., Haijen, E., Kaelen, M., & Watts, R. (2017). Psychedelics and connectedness. Psychopharmacology, 235(2), 547-550.

Chi, T., & Gold, J. A. (2020). A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. Journal of the Neurological Sciences, 411, 116715.

Davis, A. K., Agin-Liebes, G., España, M., Pilecki, B., & Luoma, J. (2021). Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States. Journal of Psychoactive Drugs, 1-10.

Dinis-Oliveira, R. J., Pereira, C. L., & Dias da Silva, D. (2019). Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology, 12(3), 184-194.

Feduccia, A. A., & Mithoefer, M. C. (2018). MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Progress in Neuro-Psychopharmacology and Biological Psychiatry, 84, 221-228.

Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases. The Journal of Nervous and Mental Disease, 202(7), 513-520.

Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 29(3), 280-288.

Hofmann, A. (2019). LSD, my problem child; and, Insights/outlooks. Beckley Foundation.

Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics, 197, 83-102.

Malcolm, B., & Thomas, K. (2021). Serotonin toxicity of serotonergic psychedelics. Psychopharmacology.

Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016). Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression. Journal of Clinical Psychopharmacology, 36(1), 77-81.

Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nature Reviews Neuroscience, 21(11), 611-624.

Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. Journal of Humanistic Psychology, 57(5), 520-564.

How to cite this paper

Should Psychedelic Drugs Be Offered as a Treatment for Mental Illness?

How to cite this paper: Ruoqi Zhang. (2023) Should Psychedelic Drugs Be Offered as a Treatment for Mental Illness? Journal of Humanities, Arts and Social Science7(2), 299-302.